MedPath

Hyaluronic acid

Generic Name
Hyaluronic acid
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C28H44N2O23
CAS Number
9004-61-9
Unique Ingredient Identifier
S270N0TRQY
Background

Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934. Karl Meyer and John Palmer obtained glycosaminoglycan (GAG) from the bovine eye, giving it the name “hyaluronic acid”. HA is involved in many important physiological processes, including but not limited to wound healing, tissue regeneration, and joint lubrication. It demonstrates unique viscoelasticity, moisturizing, anti-inflammatory qualities, and other important properties that prove beneficial in various clinical applications.

HA is used in drug delivery systems for the treatment of cancer, ophthalmological conditions, joint conditions, and aesthetic imperfections. Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms. A popular use of hyaluronic acid in recent years is cosmetic injection due to its ability to minimize the appearance of wrinkles and aging-related skin imperfections.

Indication

The intra-articular preparations of hyaluronic acid are indicated for knee pain associated with osteoarthritis. Hyaluronic acid is used in cosmetic applications to prevent and reduce the appearance of wrinkles on the face, and as a dermal filler to correct facial imperfections or other imperfections on other parts of the body. It is frequently an ingredient in topical applications for wound healing and symptomatic treatment of skin irritation from various causes. Hyaluronic acid may also be indicated in ophthalmological preparations or oral capsules to treat discomfort caused by dry eyes or conjunctivitis and for its protective qualities during and before eye surgery. Finally, hyaluronic acid can be used off-label to coat the bladder for relief of interstitial cystitis symptoms.

Associated Conditions
Actinic Keratosis (AK), Burns, Chronic Skin Ulcers, Conjunctivitis, Dehydration, Dermabrasion, Dermatosis, Dry Eyes, Facial Defect, Interstitial Cystitis, Keratoconjunctivitis, Ocular Irritation, Osteoarthritis (OA), Pain of the knee, Seasonal Allergic Conjunctivitis, Skin Burn, Skin Irritation, Skin fissures, Tissue Adhesions, Varicose Ulcers, Wound, Eye discomfort, Facial fine wrinkling, Sensation of burning in the eyes, Superficial Wounds
Associated Therapies
Dermal Filler, Promotion of wound healing, Synovial Fluid Lubrication

Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration

Phase 2
Completed
Conditions
Dehydration
Interventions
First Posted Date
2014-10-16
Last Posted Date
2019-03-07
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
51
Registration Number
NCT02265575
Locations
🇰🇪

Sagam Community Hospital, Luanda, Kenya

Comparison of Autologous Platelet-rich Plasma With Hyaluronic Acid for the Treatment of Osteoarthritis of the Knee Joint

Phase 3
Completed
Conditions
Osteoarthritis, Knee
Interventions
Biological: PRP
Drug: Hyaluronic acid
First Posted Date
2014-08-07
Last Posted Date
2015-12-10
Lead Sponsor
Samsung Medical Center
Target Recruit Count
110
Registration Number
NCT02211521
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects

Phase 2
Completed
Conditions
Poisoning by BCG Vaccine
Interventions
First Posted Date
2014-08-04
Last Posted Date
2015-05-28
Lead Sponsor
University of Rome Tor Vergata
Target Recruit Count
30
Registration Number
NCT02207608

Effect of Hyaluronic Acid in the Treatment of Periodontal Pockets

Not Applicable
Completed
Conditions
Chronic Periodontitis With Infra-bony Defects
Interventions
First Posted Date
2014-06-23
Last Posted Date
2017-07-27
Lead Sponsor
Damascus University
Target Recruit Count
30
Registration Number
NCT02170857
Locations
🇸🇾

Department of Periodontics, University of Damascus Dental School, Damascus, Syrian Arab Republic

Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells

Phase 1
Completed
Conditions
Osteoarthritis
Interventions
Drug: Hyaluronic acid
Biological: 10 million Bone marrow mesenchimal stem cells
Biological: 100 million Bone marrow mesenchimal stem cells
First Posted Date
2014-04-25
Last Posted Date
2017-10-24
Lead Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Target Recruit Count
30
Registration Number
NCT02123368
Locations
🇪🇸

Orthopaedic and traumatology department. Clínica Universidad de Navarra, Pamplona, Navarra, Spain

🇪🇸

Traumatology department. Complejo Hospitalario de Salamanca, Salamanca, Castilla y León, Spain

Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients

Phase 4
Completed
Conditions
Hip Osteoarthritis
Interventions
First Posted Date
2014-03-13
Last Posted Date
2018-08-10
Lead Sponsor
Laval University
Target Recruit Count
38
Registration Number
NCT02086474
Locations
🇨🇦

Pavillon de l'Éducation Physique et des Sports - Université Laval, Quebec, Canada

Effect Of Plasma Rich In Growth Factors In Knee Osteoarthritis

Phase 3
Completed
Conditions
Knee Osteoarthritis
Interventions
Biological: Plasma rich in growth factors
Drug: Hyaluronic Acid
First Posted Date
2014-01-17
Last Posted Date
2015-05-05
Lead Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias
Target Recruit Count
96
Registration Number
NCT02039531
Locations
🇪🇸

Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain

Intravesical Instillation of Hyaluronic Acid to Decrease Incidence of Urinary Tract Infection

Phase 4
Withdrawn
Conditions
Urinary Tract Infection
Interventions
First Posted Date
2014-01-14
Last Posted Date
2019-04-24
Lead Sponsor
Rabin Medical Center
Registration Number
NCT02034890
Locations
🇮🇱

Urology department, Rabin Medical Center, Petach Tiqva, Israel

A Comparison Between Sonoguided Injection Corticosteroid and Hyaluronic Acid Injection in Treatment of Trigger Finger

Not Applicable
Completed
Conditions
Trigger Finger
Interventions
First Posted Date
2013-09-25
Last Posted Date
2014-11-04
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
36
Registration Number
NCT01950793
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

Humectant Activity of a New Formulation of Gynomunal® Vaginalgel

Phase 4
Completed
Conditions
Vaginal Dryness
Menopause
Interventions
First Posted Date
2013-09-23
Last Posted Date
2013-09-23
Lead Sponsor
Derming SRL
Target Recruit Count
28
Registration Number
NCT01948583
Locations
🇮🇹

DermIng S.r.l, Monza, MB, Italy

© Copyright 2025. All Rights Reserved by MedPath